Trade Name Cofactor Designation Date Designation Contact Company / Onconova Therapeutics Inc. / 317 Infinity Pharmaceuticals Inc. / AbbVie Inc / QLT Inc. / Lumena Pharmaceuticals Inc. / Atterocor Inc. / 317 Microbiotix Inc. / DARA BioSciences / Khondrion BV / Catalyst Pharmaceutical Partners / glioma Inc. / 317 Lumena Pharmaceuticals Inc. / Name Designation Date Designation Contact Company / CytRx Corporation / Mundipharma Research Ltd. / Contact Company/Sponsor Murigenetics SAS Meritage Pharma Inc. / Convergence Pharmaceuticals Ltd. / Genzyme Corporation / Cortice Biosciences Inc. / Therapeutics Inc. / NeOnc Technologies / Fujisawa / Pfizer Inc. / Novartis Pharmaceuticals / Pharmaceuticals' Inc. / Name Trade Name Designation Date Designation Contact Company / Lung Therpeutics Inc. / Otsuka Pharmaceutical Company Ltd / Almirall S.A. / Glioma NATCO Pharma Limited / 317 Phase 2 Discovery Inc. / Pulmokine Inc. / Contact Company/Sponsor Ferrokin BioSciences Inc. / Research Limited / transplantation Inc. / VivoLux AB / Albireo AB / Date Designation Contact Company / Auris Medical Inc. / NATCO Pharma Limited / Fragile X syndrome Corp. / analgesics Inc. / 317 Vertex Pharmaceuticals Inc. / Discoveries Inc. / /
Event
FDA Phase / /
Facility
terminal UkUnhibitor / /
IndustryTerm
Treatment of pancreatic cancer / Treatment of Fragile X syndrome / lymphoma Therapeutics / 4/2012 syndrome Prevention / Treatment of alagille syndrome / Treatment of Gaucher disease / Treatment of cystic fibrosis / Treatment of chronic lymphocytic leukemia / inherited mitochondrial respiratory chain / Treatment of circadian rhythm sleep disorders / Treatment of Fabry's disease / /
Orphan_Drug_Designation_List_governs_April-June 2015.xlsx